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Abstract
Background: There is renewed acknowledgement that targeting gametocytes is essential for malaria control and 
elimination efforts. Simple mathematical models were fitted to data from clinical trials in order to determine the mean 
gametocyte circulation time and duration of gametocyte carriage in treated malaria patients.
Methods: Data were used from clinical trials from East Africa. The first trial compared non-artemisinin combination 
therapy (non-ACT: sulphadoxine-pyrimethamine (SP) plus amodiaquine) and artemisinin-based combination therapy 
(ACT: SP plus artesunate (AS) or artemether-lumefantrine). The second trial compared ACT (SP+AS) with ACT in 
combination with a single dose of primaquine (ACT-PQ: SP+AS+PQ). Mature gametocytes were quantified in 
peripheral blood samples by nucleic acid sequence based amplification. A simple deterministic compartmental model 
was fitted to gametocyte densities to estimate the circulation time per gametocyte; a similar model was fitted to 
gametocyte prevalences to estimate the duration of gametocyte carriage after efficacious treatment.
Results: The mean circulation time of gametocytes was 4.6-6.5 days. After non-ACT treatment, patients were estimated 
to carry gametocytes for an average of 55 days (95% CI 28.7 - 107.7). ACT reduced the duration of gametocyte carriage 
fourfold to 13.4 days (95% CI 10.2-17.5). Addition of PQ to ACT resulted in a further fourfold reduction of the duration of 
gametocyte carriage.
Conclusions: These findings confirm previous estimates of the circulation time of gametocytes, but indicate a much 
longer duration of (low density) gametocyte carriage after apparently successful clearance of asexual parasites. ACT 
shortened the period of gametocyte carriage considerably, and had the most pronounced effect on mature 
gametocytes when combined with PQ.
Background
The transmission of malaria depends on the presence of
mature sexual stage parasites, gametocytes, in the human
peripheral blood. Once ingested by a mosquito taking a
blood meal, gametocytes develop through different mos-
quito-specific stages that ultimately render the mosquito
infectious to humans. There is renewed acknowledge-
ment that targeting gametocytes, either alone or as part
of integrated control programmes, is essential for malaria
control and elimination efforts [1-4].
Plasmodium falciparum gametocytes are relatively
insensitive to many anti-malarials [5] and circulate for a
longer period of time than gametocytes of other malaria
species [6,7]. The mean circulation time per gametocyte
has been estimated at 3.4 [8], but also at 6.4 days [9].
These mean values do not reflect the broad range in the
time that a single person carries gametocytes. Following
efficacious clearance of asexual parasites, the source of
gametocyte production, the duration of gametocyte car-
riage is determined by the maximum duration of gameto-
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cyte sequestration and the maximum circulation time
following their release into the bloodstream. Maximum
gametocyte sequestration time was previously estimated
at 12 days; maximum circulation time at 22.2 days [9]. As
a consequence, gametocyte carriage in individual patients
may be as long as 3-6 weeks after a radical cure of infec-
tion [9-11] and possibly even longer if molecular detec-
tion tools are used for gametocyte detection. Microscopy
is notoriously insensitive for detecting low density game-
tocytes [6,12] while molecular assays are sufficiently sen-
sitive to detect and quantify gametocytes at densities as
low as 0.02-0.1 gametocytes per microlitre [4]. These
submicroscopic gametocyte densities can lead to infec-
tions in mosquitoes [13,14]. The use of molecular tech-
niques has revealed that 80-90% of symptomatic malaria
cases may carry gametocytes at clinical presentation and
that this gametocyte carriage may persist for several
weeks after successful treatment [15,16]. There is, there-
fore, a need to revisit previous estimates of the mean cir-
culation time of gametocytes and the duration of
gametocyte carriage using molecular detection tools.
Understanding the duration of gametocyte carriage is
particularly important for determining the role of game-
tocytocidal anti-malarial drugs in the elimination of
malaria [3]. The impact of widely used artemisinin-based
combination therapy (ACT) on gametocyte carriage is
pronounced [17,18] but not fully understood. The effect
of artemisinins may be restricted to immature gameto-
cytes [3,19-21] and may even be incomplete against these
stages [22]. However, two in vitro studies observed addi-
tional activity of artemisinins against mature gametocytes
[20,21] although for one study this could be explained by
incomplete gametocyte synchronization [20]. In vivo
studies commonly observe that mature gametocytes can
persist after ACT treatment and result in post-treatment
malaria transmission [16,22-24]. Primaquine (PQ) may
have a more pronounced effect against mature gameto-
cytes [3,11,19,25] although detailed field data are scarce,
particularly in Africa where reports are inconclusive
about the added value of PQ in clearing gametocytes per-
sisting after ACT [15,26].
Here, by fitting simple mathematical models to data
from two field trials which used sensitive molecular
gametocyte detection methods, the mean gametocyte
circulation time was determined and the full duration of
gametocyte carriage was estimated in patients treated
with non-ACT and gametocytocidal ACT and ACT-PQ
drug combinations.
Methods
Data were used from two clinical trials. Characteristics of
the studies are summarized in table 1. The first trial was
conducted in 2003 and 2004 in Mbita, western Kenya
where the entomologic inoculation rate (EIR) was ~70
infectious bites per person per year (ibpy)[27]. This trial
compared sulphadoxine-pyrimethamine alone (SP: 25
mg/kg S + 1.25 mg/kg P as single dose) or in combination
with artesunate (AS: 4 mg/kg once daily for 3 days) or
amodiaquine (AQ: 10 mg/kg once daily for three days)
with treatment with artemether lumefantrine (AL: 10 mg
A + 60 mg L/5 kg twice daily for three days) [16,28]. The
second trial was conducted in 2006 in Mnyuzi, northeast-
ern Tanzania (EIR ~10 ibpy [29]) and compared treat-
ment with SP+AS with SP+AS followed by a single dose
of primaquine (PQ: 0.75 m/kg once on the last (third) day
of treatment)[15,30]. Both trials had similar inclusion cri-
teria, enrolling children with uncomplicated malaria with
a P. falciparum infection at a density of 500 - 100,000 par-
asites/μL and no microscopical evidence of co-infection
with other Plasmodium species. Two microscopists each
read 100 high power microscopic fields for asexual para-
sites. The trial in Kenya included children aged 0.5-10
years and excluded children with an Hb < 5 g/dL; the trial
in Tanzania included children aged 3-15 years and
excluded children with an Hb < 8 g/dL. Parents or guard-
ians provided written informed consent for enrolment
and the trial protocols received ethical clearance in Kenya
(Scientific Steering Committee and Ethical Review Com-
mittee of the Kenya Medical Research Institute; SSC No.
791), Tanzania (National Institute for Medical Research;
NIMR/HQ/R.8a Vol. XIII/446) and the UK (London
School of Hygiene and Tropical Medicine #4097).
Gametocyte detection
Gametocyte carriage was determined on day 0, 3, 7, 14,
28 after treatment; treatment (d0-2) was completed 24
hours before the second time-point for gametocyte
detection. For the trial in Tanzania, gametocyte carriage
was also determined on day 42. In both studies, gameto-
cyte prevalence and density were determined by examin-
ing 100 microscopic fields specifically for gametocytes
and by quantitative nucleic acid sequence based amplifi-
cation (QT-NASBA). The latter method is based on the
detection of Pfs25 mRNA that is expressed in mature
gametocyte (stage V) gametocytes [31] and has a sensitiv-
ity of 0.02-0.1 gametocyte per μL [32]. Enrolment game-
tocyte prevalence in the different treatment arms was 19-
26% by microscopy and 85-92% by QT-NASBA [15,16].
Data analysis
This study aimed to determine the mean circulation time
of gametocytes and the impact of ACT and PQ on exist-
ing gametocyte carriage. Therefore, individuals were
selected who i) had gametocytes by Pfs25 QT-NASBA at
any time between day 0 and day 28 after enrolment, ii)
were successfully cured of their asexual parasites (defined
as no asexual parasites after day 3 and a day 3 asexual
density≤10% of the day 0 density) and had no detectable
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re-infection. SP-treated children experienced a very high
treatment failure rate by microscopy (56%). Additional
low level SP-treatment failures may have been missed by
day 28 [33] and the slow parasite clearance time probably
extended the generation of gametocytes from asexual
stages after the initiation of SP treatment [34]. The SP
monotherapy arm was therefore completely excluded
from the current analyses. Instead, models were fitted on
data from i) SP+AQ treated individuals (non-ACT arm)
since this drug combination had a high efficacy and rapid
asexual parasite clearance time [16,35] but no activity
against mature gametocytes[5]; ii) SP+AS and AL treated
individuals that were combined as the ACT-arm since
both drug combinations had an indistinguishable impact
on gametocyte carriage [16]; iii) SP+AS+PQ (ACT-PQ)
treated children. Frequent re-infections rendered the data
from the trial in Tanzania less reliable after day 28 [15]
and, therefore, only data up to this time-point were con-
sidered. Two phases in gametocyte carriage after treat-
ment were considered. The first phase comprises day 0-3
when short acting artemisinins [36] and PQ [37,38] may
have a direct effect on gametocyte densities and gameto-
cyte densities may be influenced by an efflux of seques-
tered gametocytes as a result of the drug treatment
induced 'stress' [7]. The initial reduction in gametocyte
carriage in this period was quantified by expressing the
gametocyte density on day 3 as a proportion of the enrol-
ment density for the three treatment arms. The second
phase was defined as day 3 till day 28 (end of follow-up)
and was used to estimate the mean circulation time of
gametocytes after asexual parasites have been cleared and
gametocytocidal drug levels have waned.
Mathematical model
A simple deterministic compartmental model describing
the gametocyte density per μL blood over time (Figure 1)
was fitted to data on gametocyte density to estimate the
circulation time per gametocyte. A second similar model
with a prevalence framework rather than a density frame-
work, describing the appearance of gametocytes in the
blood (if not already present on day 0) and the time until
they were fully cleared from the blood, was fitted to
gametocyte prevalence data, to estimate the mean overall
duration of gametocyte carriage in a patient following
treatment (Figure 1). The structure of these models was
similar to those of Hogh et al [39]. Both models assumed
Table 1: Baseline description of the two studies that provided data for the current analysis
Kenya, 2003-2004 Tanzania, 2006
Number of participants 160* 108
Age, median (IQR) 3 (1-5) 5 (3-9)
Drugs, (n) Non-ACT: SP+AQ (127)
ACT: SP+AS (174) & AL (75)
ACT: SP+AS (54)
ACT-PQ: SP+AS+PQ (54)
Enrolment asexual microscopic parasite 
density, geometric mean (95% CI)
11,813 (9,690 - 14,402) 7,440 (1,000 - 24,280)
Microscopic gametocyte prevalence at 
enrolment, % (n/N)
25.5 (40/157) 22.6 (24/106)
Pfs25 QT-NASBA gametocyte prevalence 
at enrolment, % (n/N)
Non-ACT: 91.1 (41/45):
ACT: 89.3 (100/112)
ACT: 88.2 (45/51)
ACT-PQ: 92.3 (48/52)
Pfs25 QT-NASBA gametocyte density at 
enrolment, geometric mean/μL (95% CI)
Non-ACT: 1.22 (0.58-2.56)
ACT: 0.66 (0.42-1.03)
ACT: 20.26 (8.08-50.37)
ACT-PQ: 9.90 (4.43-22.11)
Included in current model fitting analysis Non-ACT: 36¶
ACT: 90¶
ACT: 36¥
ACT-PQ: 41¥
IQR = interquartile range; SP = Sulphadoxine-pyrimethamine; AQ = amodiaquine; AS = artesunate; AL = artemether-lumefantrine; PQ: 
primaquine. * SP treated individuals (n = 152) or those without QT-NASBA data (n = 216) were excluded from the current analyses; ¶34 
individuals were excluded because of treatment failure (n = 28) and/or failure to develop gametocytes during follow-up (n = 6); ¥26 
individuals were excluded because of treatment failure (n = 21) and/or failure to develop gametocytes during follow-up (n = 8) and/or 
missing data (3).
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no further generation of gametocytes from asexual stages
once treatment had been initiated; however, gametocytes
were assumed to emerge from sequestration into the
peripheral blood. The two models were fitted separately
to data from individuals grouped according to treatment
type into three previously described groups: non-ACT,
ACT and ACT-PQ.
In the density model, the gametocyte concentration in
the bloodstream G changes over time depending on the
rate of release of gametocytes into the bloodstream ρ
from a sequestered gametocyte population S, and on the
decay rate μ of the circulating gametocytes. Exponentially
distributed sequestration and decay times were assumed,
so that 1/ρ gives the mean sequestration time and 1/μ is
the mean circulation time per gametocyte. The differen-
tial equations describing this process are given by:
This is solved to obtain an expression for the expected
gametocyte density in circulation at time t since treat-
ment began, G(t), where S0 is the density of the seques-
tered gametocyte population on day 0, and G0 is the
density of circulating gametocytes on day 0:
The model was fitted to the log gametocyte densities
using maximum likelihood methods, assuming a Normal
distribution for the log transformed data and incorporat-
ing Normally-distributed random effects for each patient
in overall density. Zero density values in the data were
treated as values below the detection limit of the assays
(0.02 gametocytes/μL for the QT-NASBA method) and
the likelihood was specified to account for these censored
observations. Each trial was fitted separately as there was
a significant difference in initial log gametocyte density
between trials and therefore other factors may also have
differed between the two study populations. Gametocyte
circulation time was allowed to vary by treatment type,
since both ACT and PQ may have differing effects. The
initial size of the sequestered gametocyte population was
an uncertain parameter. As well as estimating this param-
eter from the model fitting, a sensitivity analysis was
undertaken for a range of fixed values. Because ACT is
likely to clear immature gametocytes before they can be
released into sequestration, we fixed the sequestered
gametocyte population to be 3 log lower than for the
non-ACT treatment (Table 2). The rate of release of
sequestered gametocytes, and any differences between
treatment groups in the initial size of the sequestered
gametocyte population could not be estimated indepen-
dently from other parameters but was assumed to be sim-
ilar between treatment groups within trials. Different
fixed values were therefore fitted for the size of the
sequestered gametocyte population that was subse-
quently released into the circulation in a sensitivity analy-
sis (Additional file 1). The duration of the sequestration
period per gametocyte was previously determined at 4-12
days [9]; we fitted different values within this range and
fixed the sequestration time to 11 days based on the best
fit (Table 2).
The gametocyte prevalence model describes the
appearance and disappearance of any circulating gameto-
cytes according to the prevalence at day 0, I0, the rate f at
which initially gametocyte-negative proportion E move
to the gametocyte-positive state I, and the rate r at which
infectious individuals recover to become gametocyte
negative. The equations describing this process are given
by:
This can be solved to obtain an expression for the
expected prevalence of gametocytes in the patients t days
after treatment, I(t), as:
The model was fitted to the individual patient preva-
lence data using maximum likelihood methods assuming
a Binomial outcome distribution and random patient
effects Normally distributed on the logit scale. The rate of
loss of gametocytaemia, r, was allowed to vary by treat-
dS
dt
S
dG
dt
S G
= −
= −
r
r m
G t e G S
e t e tt( ) = +
−
−
−
−
−m r
m r
r m0 0
dE
dt
fE
dI
dt
fE rI
= −
= −
I t e I f I
e rt e ft
f r
rt( ) ( )= + −
−
−
−
−
−
0 01
Figure 1 Models describing change in gametocyte density and 
gametocyte prevalence over time. S, sequestered gametocytes; G, 
circulating gametocytes; E, gametocyte-negative infected individuals 
(i.e. gametocytes not yet released into circulation); I, gametocyte-pos-
itive individuals; ρ rate of release of gametocytes from sequestration 
into the bloodstream; μ, rate of decay/removal of gametocytes; f, rate 
at which gametocyte-negative individuals become gametocyte-posi-
tive; r, rate at which gametocyte-positive individuals become gameto-
cyte negative.
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ment type, while the other parameters were assumed to
be constant between groups. The rate of becoming game-
tocyte positive, f, was estimated from the data, and also
varied in sensitivity analysis [40]. The time to positivity
and the duration of infectiousness were assumed to be
exponentially distributed with means given by 1/f and 1/r,
respectively. To obtain the predicted marginal probabili-
ties of gametocyte positivity at each time point for each
treatment group from estimated parameters, 10,000 val-
ues were simulated from the random effects distribution
using the estimated variance from the model, added to
the logit transformed model prediction, then trans-
formed back to the prevalence scale.
All model fitting was carried out using the PROC
NLMIXED procedure in SAS (Version 9.1, SAS Institute
Inc, USA).
Results
The numbers and characteristics of individuals included
in the analysis are summarised in table 1. While there
were no statistically significant differences in asexual par-
asite density or gametocyte prevalence or density
between treatment arms within the trials [15,16], baseline
values differed between trials. The density of asexual par-
asites was higher and the gametocyte density was lower
in the trial in Kenya compared to the trial in Tanzania.
The circulation time of gametocytes
The mean circulation time of gametocytes was estimated
using Pfs25 QT-NASBA gametocyte density data. The
data indicated an approximately linear decrease in log-
gametocyte density between day 3 and day 28 (Figure 2),
except in the ACT-PQ group where the gametocyte den-
sity rapidly approached zero (Figure 3). This gradual
decline in gametocyte density was interpreted as the nat-
ural decay of gametocytes after peak gametocytocidal
drug levels had waned [41]. When this time-frame (day 3-
28) was used to fit the natural decay rate of gametocytes
in the Kenyan trial, the mean gametocyte circulation time
was estimated at 6.5 days (95% CI 4.8-8.8) and 5.0 days
(95% CI 4.2-6.1) in the non-ACT and ACT treated indi-
viduals, respectively, with no statistically significant dif-
ference between the groups (p = 0.144). Using the same
methodology, the mean gametocyte circulation time was
4.6 days (95% CI 2.9-7.3) after ACT in the Tanzanian trial
(Figure 3). This estimate was lower than that of the trial
Table 2: Other parameters used or estimated in density and prevalence models using QT-NASBA data
Parameter Description Estimates (95% CI)
Kenya, 2003-2004 Tanzania, 2006
Density model
1/ρ 1/duration of gametocyte sequestration, days 1/11 1/11
S3* size of sequestered gametocyte population on 
day 3 that is subsequently released into the 
circulation
Non-ACT: 0.0263 ACT: 0.0013 0.0013 (0.0001-0.0237)
G3¶ density of circulating gametocytes/μL on day 3 
after start treatment
non-ACT: 1.45 (0.44-4.74)
ACT: 0.13 (0.03-0.52)
ACT: 1.88 (0.37-9.52)
ACT-PQ: 0.07 (0.01-0.86)
Prevalence model
1/f ¥ time until patients gametocyte-negative on 
day 0 become gametocyte-positive, days
5.60 5.60 (1.06-29.4)
All values with confidence intervals were estimated in the model; values without confidence intervals were fixed unless stated otherwise.
* estimated based on the trial data, expressed as the total sequestered population that would be released per μL of blood. Details of the 
sensitivity analysis for this parameter are given in table S1. The value presented here is a product of the baseline sequestered gametocyte 
density and the immediate impact of anti-malarial drugs on days 0, 1 and 2.
¶estimated based on the data for each trial and treatment arm separately. The density of circulating gametocytes at enrolment was not 
different between arms within trials (table 1). The value presented here is a product of the baseline gametocyte density and the immediate 
impact of anti-malarial drugs on days 0, 1 and 2.
¥Estimated from the data in the trial in Kenya. The number of children who became gametocytaemic during the trial while being gametocyte 
negative at enrolment was 3 (out of 4 gametocyte negative individuals) for non-ACT in Kenya, 9 (out of 12) for ACT in Kenya, 2 (out of 6) for 
ACT in Tanzania and 0 (out of 4) for ACT-PQ in Tanzania.
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in Kenya, although the difference was not statistically sig-
nificant (p = 0.670). The gametocyte circulation time of
patients treated with ACT-PQ was estimated to be signif-
icantly lower at 0.5 days (95% CI 0.2-1.2) (p < 0.001).
The impact of drugs on gametocyte carriage
Prior to the gradual decline of gametocyte densities
between day 3 and day 28, there was a sharp reduction in
gametocyte densities in the ACT arm in the Kenyan trial.
In children in the ACT group who carried gametocytes at
enrolment, the density of gametocytes fell by a median of
90.9% (IQR 39.0-100.0%; p < 0.001) between day 0 and
day 3. In the Tanzanian trial, the median reduction in
gametocyte density between day 0 and day 3 after initia-
tion of ACT treatment was 67.7% (IQR 33.5-95.3%, p <
0.001). There was no statistically significant change in
gametocyte density in the first three days after initiation
of efficacious non-ACT treatment (p = 0.10). The ACT-
PQ combination had a stronger and longer impact on
gametocyte carriage than ACT alone. The gametocyte
density decreased very sharply between day 0 and day 3
(median reduction 99.1%, IQR 71.8-100%) and, rather
than a gradual decline, continued to decrease sharply
afterwards. Between day 3 and day 7, gametocytes were
cleared for 76.9% (20/26) of the children who still had
gametocytes by day 3. Only 4.9% (2/41) of all gametocy-
taemic children at enrolment still had detectable levels of
gametocytes by day 14 after ACT-PQ treatment. Between
day 14 and day 28, one of these two individuals remained
gametocytaemic. Four others became gametocytaemic
after being gametocyte free on day 3, 7 and 14 (n = 3) or
on day 7 and 14 (n = 1), suggesting that their gametocytes
were produced by a newly acquired infection or parasites
that emerged from the liver or recrudesced after treat-
ment was initiated.
The variation between study drugs and trials was
reflected in the estimated duration of gametocyte car-
riage after treatment (Table 3). It was necessary to esti-
mate the duration of gametocyte carriage with a model
because it was beyond the last time point of follow-up for
some drugs. In the trial in Kenya, the mean duration of
gametocyte carriage was estimated to be 55.6 (95% CI
28.7 - 107.7) days after successful non-ACT treatment;
48.3 (14/29) of the children still harboured gametocytes
on day 28 after non-ACT treatment (Figure 4). In the
same trial, the use of ACT resulted in a four-fold reduc-
tion of the estimated duration of gametocyte carriage
compared to non-ACT (13.4 days; 95% CI 10.2-17.5). The
duration of gametocyte carriage after ACT treatment was
longer in the trial in Tanzania compared to the trial in
Kenya (28.6 days; 95% CI 17.0 - 48.0; p = 0.011). Addition
of PQ to ACT resulted in a marked fourfold reduction in
Figure 2 The mean gametocyte circulation time based on Pfs25 
QT-NASBA gametocyte density after non-ACT and ACT. Log game-
tocyte density/μL is given on the Y-axis, the day of follow up after initi-
ation of treatment. Symbols and error bars indicate the field data with 
95% confidence interval, lines fitted values. The dotted line indicates 
the lower threshold for gametocyte detection by QT-NASBA, 0.02 
gametocytes/μL. The trial was conducted in Kenya; treatment regi-
mens were non-ACT (open diamonds; SP+AQ administered on day 0-
2) and ACT (closed triangles; SP+AS or AL administered on day 0-2). 
The estimated mean circulation time of gametocytes in this trial was 
6.53 days (95% CI 4.84-8.80) after non-ACT treatment and 5.04 days 
(95% CI 4.20-6.06) after ACT treatment, based on data between d3 and 
d28.
Figure 3 The mean gametocyte circulation time based on Pfs25 
QT-NASBA gametocyte density after ACT and ACT-PQ. Log game-
tocyte density/μL is given on the Y-axis, the day of follow up after initi-
ation of treatment. Symbols and error bars indicate the field data with 
95% confidence interval, lines fitted values. The dotted line indicates 
the lower threshold for gametocyte detection by QT-NASBA, 0.02 
gametocytes/μL. The trial was conducted in Tanzania; treatment regi-
mens were ACT (closed triangles; SP+AS administered on day 0-2) and 
ACT-PQ (open squares; SP+AS administered on day 0-2 followed by a 
single dose of PQ on day 2). The mean circulation time of gametocytes 
in this trial was 4.61 days (2.92 - 7.26) after ACT treatment and 0.53 days 
(0.24-1.19) after ACT-PQ treatment.
Bousema et al. Malaria Journal 2010, 9:136
http://www.malariajournal.com/content/9/1/136
Page 7 of 11
the duration of gametocyte carriage to 6.3 (95% CI 4.7-
8.5) days (Figure 5).
Discussion
In the current study, previous estimates of the circulation
time of P. falciparum gametocytes were revisited using
sensitive molecular gametocyte detection methods. The
mean circulation time of gametocytes was 4.6-6.5 days,
depending on the study site. Gametocyte carriage per-
sisted for an estimated average of 55 days after the initia-
tion of treatment that resulted in the apparent clearance
of asexual parasites. ACT shortened the period of game-
tocyte carriage considerably, particularly when combined
with PQ, a regimen that had the most pronounced effect
on mature gametocytes.
Findings on circulation time of gametocytes confirm
previous estimates that used microscopy for gametocyte
detection. Although the molecular gametocyte detection
method that was used was considerably more sensitive
for detecting low-density gametocyte carriage [4,6], the
rate of decline of gametocyte density over time was simi-
lar to that observed by microscopy [8,9]. Not surprisingly
however, the higher sensitivity for gametocyte detection
did result in a longer estimated duration of gametocyte
carriage after successful treatment. The duration of
gametocyte carriage after treatment depends on the max-
Figure 4 The duration of gametocyte carriage based on the Pfs25 
QT-NASBA gametocyte prevalence after non-ACT and ACT treat-
ment. Symbols and error bars indicate the field data with 95% confi-
dence interval, lines fitted values. The trial was conducted in Kenya; 
treatment regimens were non-ACT (open diamonds; SP+AQ adminis-
tered on day 0-2) and ACT (closed triangles; SP+AS or AL administered 
on day 0-2). The estimated average duration of gametocyte carriage 
was 55.6 days (95% CI 28.7-107.7) after non-ACT treatment and 13.4 
days (95% CI 10.2-17.5) after ACT treatment.
Table 3: The duration of gametocyte carriage and persistence of gametocytes after treatment with non-ACT, ACT and ACT-
PQ in clinical trials in Kenya and Tanzania.
Duration of gametocyte 
carriage in days (95% CI)
% still gametocytaemic during follow up (n/N)
Day 14 Day 28
Kenya, 2003-2004
Non-ACT 55.6 (28.7-107.7) 77.8 (28/36) 48.3 (14/29)
ACT 13.4 (10.2-17.5) 55.6 (50/90) 11.9 (10/84)
p-value < 0.001 0.02 < 0.001
Tanzania, 2006
ACT 28.6 (17.0-48.0) 58.3% (21/36) 38.9% (14/36)
ACT-PQ 6.3 (4.7-8.5) 4.9%(2/41) 12.2% (5/41)
p-value < 0.001 < 0.001 0.007
All individuals included in the analyses had gametocytes by Pfs25 QT-NASBA at enrolment and were successfully treated, i.e. were free of 
microscopic asexual parasitaemia between day 3 and the end of follow-up.
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imum sequestration time and the maximum circulation
time. The average gametocyte circulation time in this
study was 4.6-6.5 days, but the maximum circulation time
will considerably longer and was previously estimated at
22.2 days [9]. The field data presented in this study indi-
cate that approximately half of the children still carried
gametocytes four weeks after the initiation of efficacious
non-ACT treatment. Fitting a mathematical model to
these data, the average duration of gametocyte carriage
was 55 days after initiation of treatment. This estimate
was obtained by extrapolating the gradual decline in
gametocyte prevalence observed between day 0 and day
28 to later time-points, thereby assuming that the pattern
of loss follows an exponential distribution at a rate that
does not change with time. If however, the rate of decay
increases after day 28 the true duration of gametocyte
carriage would be lower than reported here. The duration
of gametocyte carriage can therefore not be estimated
with certainty after the last day of follow-up, day 28. The
sampling scheme was based on conventional time-points
for drug sensitivity trials and extending the follow-up to
several months would have been logistically challenging
and introduced a high chance of enumerating gameto-
cytes derived from re-infections. The estimate of 55 days
is also longer than the sum of previously reported maxi-
mum sequestration and maximum circulation times,
which would be 32 days [9]. The findings nevertheless
demonstrate that gametocyte carriage can persist for well
beyond one month after the apparent clearance of asexual
parasites and in some individuals gametocyte carriage
after efficacious non-ACT treatment may persist for lon-
ger than previous anecdotal reports of 3-6 weeks [9-11].
Although gametocyte densities and the associated likeli-
hood of malaria transmission to mosquitoes will decrease
with time, individuals may remain infectious to mosqui-
toes for several weeks after successful clearance of asex-
ual parasites [13]. This highlights the importance of the
use of gametocytocidal drugs to reduce the duration of
gametocyte carriage.
While the non-ACT combination had no activity
against mature gametocytes [5], both ACT and ACT-PQ
had a pronounced effect on the density of circulating
gametocytes. In the trial comparing non-ACT with ACT
treatment, ACT reduced the duration of gametocyte car-
riage fourfold. This was solely explained by the impact of
ACT on gametocytes in the first days of the study. After
day 3, when artemisinin concentrations are ineffective
[36], a gradual decline of gametocyte densities over time
was observed that was not different from that in non-
ACT treatment and interpreted as the natural decay of
gametocytes. This explains why the mean gametocyte
circulation time after day 3 is similar between non-ACT
and ACT while the duration of gametocyte carriage is
very different. The latter is influenced considerably by the
early effects of treatment, i.e. the reduction in gametocyte
density between day 0 and day 3. The Pfs25 mRNA-based
detection method only detects mature stage V gameto-
cytes [31]. Assuming a complete clearance of asexual par-
asites, the post-treatment concentration of mature
gametocytes in the circulation is influenced by i) the cir-
culating gametocyte density at enrolment, ii) the release
of sequestered gametocytes upon treatment [7], iii) the
natural death rate of gametocytes, iv) possible immune
clearance of gametocytes [42] and v) the activity of anti-
malarials against mature gametocytes. The difference
between non-ACT and ACT in the early reduction in
gametocyte densities is at least partly explained by the
clearance of immature sequestered gametocytes that are
released into the circulation at a much lower rate after
ACT [3,22]. While the concentration of mature gameto-
cytes remained unaltered shortly after efficacious non-
ACT (i.e. the release of sequestrated gametocytes and
decay of circulating gametocytes are in balance), the
gametocyte concentration was 65-90% lower after three
days of ACT. It is unclear whether this is (partly) the
result of an effect against mature gametocytes [21] or
solely of a rapid clearance of sequestered immature
gametocytes. One population averaged value was fitted
for the pool of sequestered gametocytes that was released
into the circulation after treatment. The best estimate
from the model was that this pool comprised less than
0.01% of the mean circulating pool of gametocytes. A
sensitivity analysis indicated that the exact value of this
Figure 5 The duration of gametocyte carriage based on the Pfs25 
QT-NASBA gametocyte prevalence after ACT and ACT-PQ treat-
ment. Symbols and error bars indicate the field data with 95% confi-
dence interval, lines fitted values. The trial was conducted in Tanzania; 
treatment regimens were ACT (closed triangles; SP+AS administered 
on day 0-2) and ACT-PQ (open squares; SP+AS administered on day 0-
2 followed by a single dose of PQ on day 2). The estimated average du-
ration of gametocyte carriage was 28.6 days (95% CI 17.0 - 48.0) after 
ACT treatment and 6.3 days (95% CI 4.7-8.5) after ACT-PQ treatment.
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parameter did not change the estimated circulation time
of gametocytes after treatment substantially unless values
of >15% of circulating gametocytes were used. The uncer-
tainty of this parameter is a shortcoming of the presented
model and a challenge for future assays for testing game-
tocytocidal drugs. Ideally, one would directly determine
the sequestered gametocyte pool for each individual to
allow for influences of peripheral blood gametocyte den-
sity and the duration of infection. For asexual P. falci-
parum parasites, it is possible to estimate the circulating
and sequestered number of parasites by measuring
plasma concentration of histidine-rich protein (PfHRP2)
[43]. A similar approach is currently unavailable for
gametocytes, but would greatly facilitate the assessment
of the activity of anti-malarial drugs against different
stages of P. falciparum gametocytes.
Addition of PQ to ACT was found to strongly increase
the clearance of remaining gametocytes [15]. A recently
published mathematical model indeed suggests that
malaria transmission may be significantly lowered in a
low transmission setting by PQ in addition to ACT [38].
Here, ACT-PQ resulted in a four-fold reduction of the
estimated duration of gametocyte carriage compared to
ACT alone. This could be partly explained by PQ clearing
liver stage infections, thereby preventing the production
of gametocytes from parasites newly released from the
liver. However, the rapid decline in mature gametocytes
upon treatment indicates that the activity against circu-
lating gametocytes will be most important. In eight indi-
viduals (8/41, 19.5%) low densities of gametocytes
persisted until the fifth day after PQ administration (day
7 after initiation of treatment) and in two individuals (2/
41, 4.9%) gametocytes persisted until the twelfth day after
PQ administration (day 14 after initiation of treatment).
PQ concentrations peak approximately two hours after
administration [37] and PQ has an elimination half-life of
approximately 8-hours [37,38]. This raises questions
about the nature of the apparent reduction of gametocyte
densities several days after PQ treatment. Previous stud-
ies also reported that microscopically detectable gameto-
cytes were detectable for several days after PQ
administration before they were eventually cleared
[19,44]. The exact mechanism by which PQ clears game-
tocytes is unknown but may be related to an effect of PQ
on mitochondrial proliferation that inhibits development
stages, such as gametocytes, that require functional mito-
chondria [45]. The cause of the observed 'delayed effect'
of PQ is unclear but exposure to (the active metabolites
of ) PQ appears to influence the longevity of mature
gametocytes that initially survive peak plasma concentra-
tions. This is reflected in a reduced estimated circulation
time per gametocyte between days 3 and 28 compared to
ACT or non-ACT treatment.
The presented analysis has several limitations in addi-
tion to the fact it is based on only two studies. The con-
founding potential of re-infections was minimised by
limiting the observation period to a time when re-infec-
tion was deemed unlikely. However, it is possible that
some low-density re-infections or persisting parasitaemia
occurred, as was suggested by the increase in gametocyte
prevalence in the trial in Tanzania after gametocytes were
cleared from all but one individual. There is currently no
molecular detection tool that specifically detects asexual
parasites with the same sensitivity as the gametocyte
Pfs25 QT-NASBA. Undetected low density infections
could have boosted gametocyte production [7] or
resulted in ongoing gametocyte production [46] and
resulted in a longer estimated duration of gametocyte
carriage. It is also impossible to exclude that parasites
newly emerging from the liver have contributed to game-
tocyte production after drug levels had waned. This does
not affect the validity of the conclusions, i.e. gametocyte
carriage can persist for several weeks after treatment, but
underlines the importance of developing new molecular
parasite detection tools to confirm the origin of post-
treatment gametocytes. These tools should be sensitive,
quantitative and stage specific. The differences between
study sites also highlight the limitations in extrapolating
findings from one study area. Gametocyte dynamics may
differ between areas [6] and the findings indicate that this
may also influence the impact of treatment on gameto-
cyte carriage. The duration of gametocyte carriage
appeared longer in the Tanzanian trial (28.6 days com-
pared to 13.4 days in Kenya). Enrolment Pfs25 QT-
NASBA gametocyte densities were higher in the Tanza-
nian trial, which may explain the observed difference,
given that ACT is thought to impact less on mature
gametocytes. Increased clonal complexity [47] and
younger age [10] have both been associated with a longer
duration of gametocyte carriage. However, these factors
cannot explain the observed difference between trials
since transmission intensity is positively correlated with
multiplicity of infection [48], but lower at the Tanzanian
site [29], where trial participants were also older.
Conclusion
The current analysis indicates that gametocytes persist
for an average of more than one month after clearance of
asexual parasites. Artemisinins can shorten the duration
of gametocyte carriage approximately fourfold. PQ is a
more potent gametocytocidal drug than artemisinins and
in led to a fourfold reduction in the duration of gameto-
cyte carriage compared to ACT alone.
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